1
|
Abstract
Cysteine cathepsins are proteases critical in physiopathological processes and show potential as targets or biomarkers for diseases and medical conditions. The 11 members of the cathepsin family are redundant in some cases but remarkably independent of others, demanding the development of both pan-cathepsin targeting tools as well as probes that are selective for specific cathepsins with little off-target activity. This review addresses the diverse design strategies that have been employed to accomplish this tailored selectivity among cysteine cathepsin targets and the imaging modalities incorporated. The power of these diverse tools is contextualized by briefly highlighting the nature of a few prominent cysteine cathepsins, their involvement in select diseases, and the application of cathepsin imaging probes in research spanning basic biochemical studies to clinical applications.
Collapse
Affiliation(s)
- Kelton A Schleyer
- Department of Medicinal Chemistry, College of Pharmacy, University of Florida, 1345 Center Dr, Gainesville, FL 32610, USA.
| | - Lina Cui
- Department of Medicinal Chemistry, College of Pharmacy, University of Florida, 1345 Center Dr, Gainesville, FL 32610, USA.
| |
Collapse
|
2
|
Morrison CN, Prosser KE, Stokes RW, Cordes A, Metzler-Nolte N, Cohen SM. Expanding medicinal chemistry into 3D space: metallofragments as 3D scaffolds for fragment-based drug discovery. Chem Sci 2019; 11:1216-1225. [PMID: 34123246 PMCID: PMC8148059 DOI: 10.1039/c9sc05586j] [Citation(s) in RCA: 75] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Accepted: 12/12/2019] [Indexed: 01/02/2023] Open
Abstract
Fragment-based drug discovery (FBDD) is a powerful strategy for the identification of new bioactive molecules. FBDD relies on fragment libraries, generally of modest size, but of high chemical diversity. Although good chemical diversity in FBDD libraries has been achieved in many respects, achieving shape diversity - particularly fragments with three-dimensional (3D) structures - has remained challenging. A recent analysis revealed that >75% of all conventional, organic fragments are predominantly 1D or 2D in shape. However, 3D fragments are desired because molecular shape is one of the most important factors in molecular recognition by a biomolecule. To address this challenge, the use of inert metal complexes, so-called 'metallofragments' (mFs), to construct a 3D fragment library is introduced. A modest library of 71 compounds has been prepared with rich shape diversity as gauged by normalized principle moment of inertia (PMI) analysis. PMI analysis shows that these metallofragments occupy an area of fragment space that is unique and highly underrepresented when compared to conventional organic fragment libraries that are comprised of orders of magnitude more molecules. The potential value of this metallofragment library is demonstrated by screening against several different types of proteins, including an antiviral, an antibacterial, and an anticancer target. The suitability of the metallofragments for future hit-to-lead development was validated through the determination of IC50 and thermal shift values for select fragments against several proteins. These findings demonstrate the utility of metallofragment libraries as a means of accessing underutilized 3D fragment space for FBDD against a variety of protein targets.
Collapse
Affiliation(s)
- Christine N Morrison
- Department of Chemistry and Biochemistry, University of California San Diego La Jolla CA 92093 USA
| | - Kathleen E Prosser
- Department of Chemistry and Biochemistry, University of California San Diego La Jolla CA 92093 USA
| | - Ryjul W Stokes
- Department of Chemistry and Biochemistry, University of California San Diego La Jolla CA 92093 USA
| | - Anna Cordes
- Lehrstuhl für Anorganische Chemie 1, Bioanorganische Chemie, Ruhr-Universität Bochum Universitätsstraße 150 44801 Bochum Germany
| | - Nils Metzler-Nolte
- Lehrstuhl für Anorganische Chemie 1, Bioanorganische Chemie, Ruhr-Universität Bochum Universitätsstraße 150 44801 Bochum Germany
| | - Seth M Cohen
- Department of Chemistry and Biochemistry, University of California San Diego La Jolla CA 92093 USA
| |
Collapse
|
3
|
Collery P, Desmaele D, Vijaykumar V. Design of Rhenium Compounds in Targeted Anticancer Therapeutics. Curr Pharm Des 2019; 25:3306-3322. [DOI: 10.2174/1381612825666190902161400] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2019] [Accepted: 08/30/2019] [Indexed: 12/25/2022]
Abstract
Background:
Many rhenium (Re) complexes with potential anticancer properties have been synthesized
in the recent years with the aim to overcome the clinical limitations of platinum agents. Re(I) tricarbonyl
complexes are the most common but Re compounds with higher oxidation states have also been investigated, as
well as hetero-metallic complexes and Re-loaded self-assembling devices. Many of these compounds display
promising cytotoxic and phototoxic properties against malignant cells but all Re compounds are still at the stage
of preclinical studies.
Methods:
The present review focused on the rhenium based cancer drugs that were in preclinical and clinical
trials were examined critically. The detailed targeted interactions and experimental evidences of Re compounds
reported by the patentable and non-patentable research findings used to write this review.
Results:
In the present review, we described the most recent and promising rhenium compounds focusing on their
potential mechanism of action including, phototoxicity, DNA binding, mitochondrial effects, oxidative stress
regulation or enzyme inhibition. Many ligands have been described that modulating the lipophilicity, the luminescent
properties, the cellular uptake, the biodistribution, and the cytotoxicity, the pharmacological and toxicological
profile.
Conclusion:
Re-based anticancer drugs can also be used in targeted therapies by coupling to a variety of biologically
relevant targeting molecules. On the other hand, combination with conventional cytotoxic molecules, such
as doxorubicin, allowed to take into profit the targeting properties of Re for example toward mitochondria.
Through the example of the diseleno-Re complex, we showed that the main target could be the oxidative status,
with a down-stream regulation of signaling pathways, and further on selective cell death of cancer cells versus
normal cells.
Collapse
Affiliation(s)
- Philippe Collery
- Society for the Coordination of Therapeutic Researches, 20220 Algajola, France
| | - Didier Desmaele
- Institut Galien, Universite Paris-Saclay, 92296 Chatenay-Malabry, France
| | - Veena Vijaykumar
- Biotechnology Department, REVA University, Bangalore, 560064, India
| |
Collapse
|
4
|
Arora K, Herroon M, Al-Afyouni MH, Toupin NP, Rohrabaugh TN, Loftus LM, Podgorski I, Turro C, Kodanko JJ. Catch and Release Photosensitizers: Combining Dual-Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers. J Am Chem Soc 2018; 140:14367-14380. [PMID: 30278123 DOI: 10.1021/jacs.8b08853] [Citation(s) in RCA: 82] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Dual action agents containing a cysteine protease inhibitor and Ru-based photosensitizer for photodynamic therapy (PDT) were designed, synthesized, and validated in 2D culture and 3D functional imaging assays of triple-negative human breast cancer (TNBC). These combination agents deliver and release Ru-based PDT agents to tumor cells and cause cancer cell death upon irradiation with visible light, while at the same time inactivating cathespin B (CTSB), a cysteine protease strongly associated with invasive and metastatic behavior. In total five Ru-based complexes were synthesized with the formula [Ru(bpy)2(1)](O2CCF3)2 (3), where bpy = 2,2'-bipyridine and 1 = a bipyridine-based epoxysuccinyl inhibitor; [Ru(tpy)(NN)(2)](PF6)2, where tpy = terpiridine, 2 = a pyridine-based epoxysuccinyl inhibitor and NN = 2,2'-bipyridine (4); 6,6'-dimethyl-2,2'-bipyridine (5); benzo[ i]dipyrido[3,2- a:2',3'- c]phenazine (6); and 3,6-dimethylbenzo[ i]dipyrido[3,2- a:2',3'- c]phenazine (7). Compound 3 contains a [Ru(bpy)3]2+ fluorophore and was designed to track the subcellular localization of the conjugates, whereas compounds 4-7 were designed to undergo either photoactivated ligand dissociation and/or singlet oxygen generation. Photochemical studies confirmed that complexes 5 and 7 undergo photoactivated ligand dissociation, whereas 6 and 7 generate singlet oxygen. Inhibitors 1-7 all potently and irreversibly inhibit CTSB. Compounds 4-7 were evaluated against MDA-MB-231 TNBC and MCF-10A breast epithelial cells in 2D and 3D culture for effects on proteolysis and cell viability under dark and light conditions. Collectively, these data reveal that 4-7 potently inhibit dye-quenched (DQ) collagen degradation, whereas only compound 7 causes efficient cell death under light conditions, consistent with its ability to release a Ru(II)-based photosensitizer and to also generate 1O2.
Collapse
Affiliation(s)
- Karan Arora
- Department of Chemistry , Wayne State University , 5101 Cass Avenue , Detroit , Michigan 48202 , United States
| | - Mackenzie Herroon
- Department of Pharmacology, School of Medicine , Wayne State University , Detroit , Michigan 48201 , United States
| | - Malik H Al-Afyouni
- Department of Chemistry and Biochemistry , The Ohio State University , Columbus , Ohio 43210 , United States
| | - Nicholas P Toupin
- Department of Chemistry , Wayne State University , 5101 Cass Avenue , Detroit , Michigan 48202 , United States
| | - Thomas N Rohrabaugh
- Department of Chemistry and Biochemistry , The Ohio State University , Columbus , Ohio 43210 , United States
| | - Lauren M Loftus
- Department of Chemistry and Biochemistry , The Ohio State University , Columbus , Ohio 43210 , United States
| | - Izabela Podgorski
- Department of Pharmacology, School of Medicine , Wayne State University , Detroit , Michigan 48201 , United States.,Barbara Ann Karmanos Cancer Institute , Detroit , Michigan 48201 , United States
| | - Claudia Turro
- Department of Chemistry and Biochemistry , The Ohio State University , Columbus , Ohio 43210 , United States
| | - Jeremy J Kodanko
- Department of Chemistry , Wayne State University , 5101 Cass Avenue , Detroit , Michigan 48202 , United States.,Barbara Ann Karmanos Cancer Institute , Detroit , Michigan 48201 , United States
| |
Collapse
|